Business Terms
Cel-Sci, FDA Agree on Biomarker-Defined Confirmatory Study for Multikine
The trial, slated to begin next year, will enroll 200 patients with newly diagnosed, advanced head and neck cancer and low PD-L1 expression.
Viracta Therapeutics Cutting 42 Percent of Workforce, Reducing Board Seats in Restructuring
The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.
Transfeminine patients have PSA levels 50 times lower than similarly aged cisgender men, obscuring interpretation of test results.
NCCN Adds Prostate Cancer to Genetic Risk Assessment Guidelines
The NCCN also recently updated genetic risk guidelines for colorectal, endometrial, and gastric cancers.
Sarepta Stops Duchenne Drug Development; Nets Higher-Than-Expected Elevidys Q3 Sales
The firm is discontinuing its SRP-5051 development program but recorded $181.0 million in Elevidys sales.
Nov 7, 2024
Ocugen Obtains $30M Credit Facility
Nov 6, 2024
Caris Life Sciences CDx Assay Nabs FDA Approval
Nov 6, 2024
Nov 4, 2024